A streamlined RNA-sequencing-only pipeline identified neoantigen peptides that triggered T-cell responses and showed antitumor efficacy in mouse breast and lung cancer models — without needing costly DNA sequencing.
RNA-only neoantigen prediction validatedEliminating the need for DNA sequencing, the pipeline identified tumor-specific peptides that triggered T-cell responses and shrank tumors in both mice and one human patient
What the researchers found
An RNA-sequencing-only computational pipeline successfully identified neoantigens in mouse breast cancer (4T1), lung cancer (LLC), and one human breast cancer patient. In vitro, these neoantigen peptides triggered specific T-cell responses in BALB/c mice and the human patient. The neoantigen peptide group showed increased CD3+/CD137+ T cells (activated, tumor-specific T cells), with significant infiltration into tumor tissues. In vivo therapeutic evaluation demonstrated significant antitumor efficacy in mouse models.
Why it matters
Neoantigen-based cancer vaccines are one of the most promising approaches in personalized oncology, but their high cost and complexity limit widespread use. By eliminating the need for DNA sequencing, this RNA-only approach could cut costs and processing time significantly, making personalized cancer vaccines more accessible. If validated in larger human studies, this could accelerate the clinical adoption of neoantigen vaccines.
How the study worked
Researchers developed an in silico neoantigen prediction pipeline using only RNA sequencing data. Predicted neoantigen peptides were synthesized and tested in vitro using autologous bone marrow-derived dendritic cells (BMDCs) and peripheral blood mononuclear cells (PBMCs) to assess T-cell activation. In vivo efficacy was evaluated in mouse 4T1 breast cancer and LLC lung cancer models. T-cell infiltration was measured using CD3 and CD137 markers.
What this study cannot tell us
Only one human breast cancer patient was included — the human validation is extremely preliminary. The mouse models (4T1, LLC) are well-established but don't capture the full heterogeneity of human tumors. The RNA-only pipeline may miss some neoantigens that are detectable only through DNA sequencing. No comparison with DNA/RNA combined approaches was presented to quantify the trade-off in sensitivity. Long-term tumor control and survival data were not reported.
How to read the evidence
This is a preclinical proof-of-concept study with mouse models and minimal human validation (one patient). The computational pipeline and in vivo efficacy are promising, but the human evidence is too limited to draw clinical conclusions.
When this study was published
Published in 2025, this study addresses a critical bottleneck in personalized cancer vaccine development at a time when neoantigen-based approaches are entering phase III clinical trials.
The bigger picture
Personalized cancer vaccines using neoantigen peptides are rapidly advancing, with several in clinical trials. The main bottleneck is the cost and complexity of sequencing each patient's tumor. This RNA-only approach addresses that bottleneck directly. Combined with advances in mRNA vaccine technology (demonstrated by COVID-19 vaccines), streamlined neoantigen identification could make truly personalized cancer treatment feasible at scale.
Questions still open
- Does the RNA-only pipeline miss clinically important neoantigens that DNA sequencing would catch?
- Can this streamlined approach be scaled to a clinical setting with rapid turnaround for individual patients?
- Would combining neoantigen peptide vaccines with checkpoint inhibitors produce synergistic antitumor effects?
Common questions
What are neoantigens and how do they make cancer vaccines possible?
Why is using only RNA sequencing a big deal for cancer vaccines?
Read the original research
RNA sequencing enables neoantigen discovery and vaccine validation in breast and lung cancer.
Frontiers in immunology, 16, 1682312
Citation
Hu, Hongye; Xiong, Yicheng; Lu, Danhong; Sun, Weihong; Su, Xiaoping; Mo, Danni; Chen, Lu; Wang, Guan; Wang, Jiayan; Zhang, Xiaohua; Lu, Mingdong; Huang, Guanli. (2025). RNA sequencing enables neoantigen discovery and vaccine validation in breast and lung cancer.. Frontiers in immunology, 16, 1682312. https://doi.org/10.3389/fimmu.2025.1682312